Evidence map›Paper›PMID 41324622›Full record

ReviewInternational urogynecology journal2026

Chapter 4.5: New Proposed Treatments for Pelvic Organ Prolapse.

Marianna Alperin, Fatima F Fitz, Caroline E Gargett, Zeliha Guler, Cheryl B Iglesia, Cassandra K Kisby, Svjetlana Lozo, Valentin Manriquez, Srikala Prasad, Carolyn W Swenson and 2 more

Abstract readReview
In one paragraph

Review in International urogynecology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marianna AlperinDepartment of Obstetrics, Gynecology, and Reproductive Sciences, Division of Urogynecology and Reconstructive Pelvic Surgery, University of California San Diego, San Diego, CA, USA. malperin@health.ucsd.edu.ORCID 0000-0002-6004-1803
Fatima F FitzDepartment of Gynecology, Sector of Urogynecology and Pelvic Floor Reconstructive Surgery, Federal University of São Paulo, São Paulo, Brazil.
Caroline E GargettThe Ritchie Centre, Hudson Institute of Medical Research, Melbourne, VIC, 3168, Australia.
Zeliha GulerDepartment of Obstetrics and Gynecology, Amsterdam UMC, Amsterdam, the Netherlands.
Cheryl B IglesiaSection of Female Pelvic Medicine and Reconstructive Surgery, MedStar Washington Hospital Center, Washington, DC, USA.
Cassandra K KisbyDepartment of Ob/Gyn, Division of Urogynecology, Duke Health, Duke University School of Medicine, Durham, NC, USA.
Svjetlana LozoColumbia University Irving Medical Center, New York, USA.
Valentin ManriquezPelvic Floor Unit. Clinical, Hospital University of Chile, Región Metropolitana, Chile.
Srikala PrasadDepartment of Urology, Government Kilpauk Medical College, Chennai, Tamilnadu, India.
Carolyn W SwensonDivision of Urogynecology & Reconstructive Pelvic Surgery, Department of Obstetrics and Gynecology, University of Utah, Salt Lake City, UT, USA.
Julie A SuyamaDepartment of Obstetrics & Gynecology, Division of Urogynecology & Reconstructive Pelvic Surgery, Virginia Commonwealth University Health, Richmond, VA, USA.
Maria A T BortoliniDepartment of Gynecology, Sector of Urogynecology and Pelvic Floor Reconstructive Surgery, Federal University of São Paulo, São Paulo, Brazil.

Funding

Duke KURe ProgramK12DK100024 · NIDDK · DUKE UNIVERSITY · PI Cindy Amundsen · 2013 to 2026
$8.4M
NIDDK NIH HHS K12 DK100024
6 · The paper itself

Abstract

Pelvic organ prolapse (POP) is a morbid and costly condition that affects millions of women worldwide. Given the shortcommings of the current treatments, novel preventative and therapeutic approaches are needed. This manuscript is part of the International Urogynaecologogy Consultation (IUC) on pelvic organ prolapse (POP) chapter four on new and novel treatments for pelvic organ prolapse. The current expert narrative review (1) highlights the rationale for novel treatments for POP; (2) summarizes the exisitng mechanistic insights into physiologic alterations needed to inform the development of novel preventative and therapeutic strategies for POP; (3) reviews relevant modern tools that can help establish causal relationships between epidemiologic risk factors and POP pathogenesis; (4) describes prevention-focused interventions and advancements in treatment-focused interventions to date; and (4) emphasizes requirements for responsible translation of discoveries into novel treatments and safe incorporation of new treatments into clinical practice. Importantly, the review underscores the need for multidisciplinary adequately funded research and training programs as an absolute prerequisite for enabling a long overdue shift in clinical paradigm-instead of relying on delayed compensatory "one-size-fits-all" treatments that do not address the underlying pathophysiology, the focus should be on preventing or mitigating POP through personalized medicine approaches supported by team science.

Indexed as

Pelvic Organ ProlapseFemaleHumansRisk FactorsBasic scienceNovel treatmentsPelvic organ prolapseRegenerative medicineTranslational research

Identifiers

PMID41324622
PMCPMC12872679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.